Simpler Grants.gov #RFA-NS-25-023

NIH HEAL Initiative Grant for Analgesic Discovery Research (R61/R33)

NIH is seeking applications for the HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33), supporting research to develop safe, effective, and non-addictive pain therapeutics. - Government Buyer: - National Institutes of Health (NIH), including sub-agencies focused on complementary health, aging, vision, child health, alcohol research, diabetes, oral diseases, neuroscience, musculoskeletal, and cancer research - Products/Services Requested: - Translational research services for analgesic discovery - Development of assays for testing potential therapeutics - Screening to identify promising compounds (hits) - Initial characterization of small molecules, biologics, and natural products as pain therapeutics - Unique/Notable Requirements: - Focus on translational research (moving discoveries toward clinical application) - Clinical trials are explicitly excluded - Eligible applicants include government, business, education, and nonprofit organizations - No cost sharing or matching required - Minimum award amount is $350,000 - No specific OEMs or vendors are named, as this is a research grant opportunity

Description

This funding opportunity supports the development of safe, effective, and non-addictive therapeutics to treat pain as part of the NIH HEAL Initiative. It encourages initial translational efforts to support drug discovery programs and advance projects to meet the entry criteria for the Pain Therapeutics Development Program. The scope focuses on developing assays for testing, screening to identify hits, and initial characterization of hits and potential therapeutic agents including small molecules, biologics, and natural products. Eligible applicants include various government entities, businesses, educational institutions, nonprofits, and other specified organizations. The award minimum is $350,000 with no cost sharing or matching requirement.

View original listing